Claus Crone Fuglsang, chief science officer and senior vice president of research and development at Novozymes, bought 2,110 shares in the Danish enzyme group on Thursday at an average share price of DKK 387.93.
The total share purchase thereby comes to DKK 818,525.60 (EUR 110,012.09), according to a statement by Novozymes Thursday evening CET.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.